Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH.

J Psychopharmacol. 2016 Jun;30(6):495-553. doi: 10.1177/0269881116636545. Epub 2016 Mar 15.

2.

Olanzapine discontinuation emergent recurrence in bipolar disorder.

Arora M, Praharaj SK.

Indian J Psychol Med. 2014 Apr;36(2):170-3. doi: 10.4103/0253-7176.130986.

3.

Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder.

Turner N, Macfadden W, Anand R, Khanna S, Rapaport MH, Haskins JT, Turkoz I, Alphs L.

Innov Clin Neurosci. 2011 Oct;8(10):19-24.

4.

Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?

Fountoulakis KN, Gonda X, Vieta E, Rihmer Z.

Ann Gen Psychiatry. 2011 Mar 24;10(1):8. doi: 10.1186/1744-859X-10-8.

5.

Pharmaceutical treatment of acute bipolar depression.

Fountoulakis KN.

F1000 Med Rep. 2010 Jun 23;2. pii: 47. doi: 10.3410/M2-47.

6.

Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis.

Tamayo JM, Zarate CA Jr, Vieta E, Vázquez G, Tohen M.

Int J Neuropsychopharmacol. 2010 Jul;13(6):813-32. doi: 10.1017/S1461145709991246. Epub 2010 Feb 4. Review.

7.

Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.

Fountoulakis KN, Vieta E.

Ann Gen Psychiatry. 2009 Jul 27;8:16. doi: 10.1186/1744-859X-8-16.

8.

Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity.

Hunsberger JG, Austin DR, Chen G, Manji HK.

Brain Res. 2009 Oct 13;1293:76-84. doi: 10.1016/j.brainres.2009.06.103. Epub 2009 Jul 10. Review.

9.

Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N, Zarate CA Jr.

Curr Pharm Des. 2009;15(14):1595-611. Review.

10.

A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania.

Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, Cunha A, Souza DO, Zarate CA Jr, Kapczinski F.

J Clin Psychiatry. 2008 Aug;69(8):1237-45.

11.

Supplemental Content

Support Center